非酒精性脂肪性肝病的治疗

Treatment of Non-Alcoholic Fatty Liver Disease.

作者信息

Scherer Antonia, Dufour Jean-François

机构信息

Department of Clinical Research, Hepatology, Inselspital, University of Bern, Bern, Switzerland.

出版信息

Dig Dis. 2016;34 Suppl 1:27-31. doi: 10.1159/000447278. Epub 2016 Aug 22.

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions from steatosis to cirrhosis and hepatocellular carcinoma. Steatosis is a benign reversible condition, which does not need treatment. Cirrhosis and hepatocellular carcinoma are the end stages of any chronic liver disease and do not have etiology-specific treatments. In this chapter, we will review treatment options for non-alcoholic steatohepatitis, which is the progressive form of NAFLD. Basically there are 2 strategies, the first of which is to address lifestyle and the second to use medication. The first approach is the most physiologic, the least expensive, but is also the most difficult to implement. The second approach, which should help patients who failed the first approach, is at the advanced clinical research stage.

摘要

非酒精性脂肪性肝病(NAFLD)涵盖了从脂肪变性到肝硬化和肝细胞癌的一系列病症。脂肪变性是一种良性可逆病症,无需治疗。肝硬化和肝细胞癌是任何慢性肝病的终末期,且没有针对病因的特异性治疗方法。在本章中,我们将回顾非酒精性脂肪性肝炎(NASH)的治疗选择,NASH是NAFLD的进展形式。基本上有两种策略,第一种是解决生活方式问题,第二种是使用药物。第一种方法是最符合生理的,成本最低,但也是最难实施的。第二种方法应有助于那些第一种方法治疗失败的患者,目前正处于临床研究的高级阶段。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索